Henry Schein, Inc. HSIC
- Market cap
- $9.5B
- P/E
- 25.0×
Follow HSIC
Henry Schein, Inc. (HSIC) EV/Sales
As of 25 September 2026, Henry Schein, Inc. (HSIC) trades at a EV/Sales of 0.9×. Over the past ten years it has ranged from 0.7× (April 2020) to 1.8× (December 2018); the current reading is higher than 28% of that period. That is above the Medical Distribution industry median of 0.6× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Annual
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.9× | 3.25% |
| FY2024 | 0.8× | (12.94%) |
| FY2023 | 1.0× | 2.72% |
| FY2022 | 0.9× | (0.30%) |
| FY2021 | 0.9× | (3.04%) |
| FY2020 | 1.0× | (8.43%) |
| FY2019 | 1.1× | (4.26%) |
| FY2018 | 1.1× | 2.19% |
| FY2017 | 1.1× | 17.17% |
| FY2016 | 0.9× | (8.87%) |
Quarterly
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.9× | 8.16% |
| Mar 2026 | 0.8× | (6.92%) |
| Dec 2025 | 0.9× | 10.80% |
| Sep 2025 | 0.8× | (9.03%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| YI 111, Inc. Sponsored ADR compare | 0.0× |
| COR Cencora, Inc. compare | 0.2× |
| CAH Cardinal Health, Inc. compare | 0.2× |
| MCK McKesson Corporation compare | 0.3× |
| COSM Cosmos Health Inc. compare | 0.4× |
| ACH Accendra Health, Inc. compare | 0.9× |
| HSIC Henry Schein, Inc. | 0.9× |
| AHG Akso Health Group Sponsored ADR compare | 1.5× |
| FOCL FocalTherics compare | 2.4× |
| Medical Distribution industry median | 0.6× |
| Healthcare sector median | 3.6× |
| Market median | 2.2× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on HSIC
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement